Please ensure Javascript is enabled for purposes of website accessibility

Why Exact Sciences Stock Skyrocketed Today

By Keith Speights – Sep 24, 2020 at 3:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked the company's preliminary liquid biopsy data.

What happened

Shares of Exact Sciences (EXAS -0.46%) were skyrocketing 26.3% higher as of 3:20 p.m. EDT on Thursday. The big jump came after the company's CEO, Kevin Conroy, presented at the Cowen Liquid Biopsy Summit.

So what

With Exact Sciences stock moving so much higher, you'd expect that Conroy's presentation was a doozy. Cowen analyst Doug Schenkel thought so. He said Exact Sciences "took a big step today to declare its intent to be a major liquid biopsy company." Liquid biopsies are blood tests that determine if a person has cancer by detecting fragments of DNA that have broken off from tumor cells.

Person holding a vial with blood next to an image of DNA

Image source: Getty Images.

Conroy discussed preliminary data for Exact Sciences' multicancer liquid biopsy screening test at the Cowen meeting. The test achieved 86% overall sensitivity (the ability to correctly identify positive cases of cancer) and 95% specificity (the ability to correctly identify negative cases with no cancer) in detecting various types of cancer, with the best results in detecting ovarian and pancreatic cancer.

Schenkel still thinks Exact Sciences' Cologuard test, which uses stool samples instead of blood samples, will "remain the gold standard for colorectal cancer." However, he's enthusiastic about the company's progress in developing a multi-cancer liquid biopsy test.

Exact Sciences hasn't received FDA clearance yet to market its liquid biopsy test. The company should have a huge growth opportunity if the test secures a green light, though.  

Now what

While liquid biopsy could eventually provide a big boost for Exact Sciences, the company's fortunes currently rely primarily on Cologuard and its Oncotype DX tests that predict the likelihood of cancer recurrence. Today's move put the healthcare stock in positive territory year to date. However, Exact Sciences will need improving third-quarter results in a little over a month to keep its momentum going.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.